Pieris Pharmaceuticals Inc Stock OTC Bulletin Board
Equities
PIRS
US7207951036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
05-15 | Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
Sales 2022 | 25.9M 0 35.29M | Sales 2023 | 42.81M 0 58.33M | Capitalization | 17.99M 0 24.51M |
---|---|---|---|---|---|
Net income 2022 | -33M - -44.97M | Net income 2023 | -24M - -32.7M | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M 0 62.77M | Net cash position 2023 | 26.37M 0 35.93M | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 93.03% |
Latest transcript on Pieris Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 69 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- PIRS Stock
- PIRS Stock